title: Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
abstract: Hypertension accelerates the progression of renal disease in patients with chronic renal failure. Doxazosin, an alpha1-antagonist, is an antihypertensive agent with a long half-life. In this study, 15 patients with chronic renal failure were treated only with doxazosin and diuretics for 6 months and their blood pressure, renal parameters and lipid profile were measured. The initial dose of doxazosin was 2 mg/day and it was titrated until blood pressure was normalized. The average dose was 5.6 mg/day. As expected, systolic and diastolic blood pressure were decreased with treatment (165/91 mmHg to 135/73 mmHg). The drop in blood pressure was associated with an increase in glomerular filtration and a decrease in plasma BUN and creatinine levels. Reduction in mean blood pressure and decrease in proteinuria had a significant positive correlation (r=0.048, p=0.007). Proteinuria was decreased from 1.8 mg/day to 1.3 mg/day with doxazosin treatment and triglycerides also decreased, while HDL-cholesterol was increased. No side effects were observed. These results indicate that doxazosin is an efficient depressor agent with renal protective actions and that higher doses of doxazosin can be safely given to patients with chronic renal failure.
authors.affiliation: Department of Medicine II and Cardiovascular Center, Kansasi Medical University, Moriguchi, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Matsubara
authors.forename: A
authors.initials: A
authors.lastname: Nose
authors.forename: Y
authors.initials: Y
authors.lastname: Shibasaki
authors.forename: H
authors.initials: H
authors.lastname: Masaki
authors.forename: A
authors.initials: A
authors.lastname: Kosaki
authors.forename: M
authors.initials: M
authors.lastname: Okigaki
authors.forename: S
authors.initials: S
authors.lastname: Fujiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka-Uchiyama
authors.forename: T
authors.initials: T
authors.lastname: Hasegawa
authors.forename: O
authors.initials: O
authors.lastname: Iba
authors.forename: E
authors.initials: E
authors.lastname: Tateishi
authors.forename: K
authors.initials: K
authors.lastname: Amano
authors.forename: T
authors.initials: T
authors.lastname: Iwasaka
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D017292:Doxazosin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012449:Safety
chemical_list: D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D017292:Doxazosin